The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins.

Research output: Contribution to journalArticle

Abstract

Angiogenesis is a key event in cancer progression and therefore a promising target in cancer treatment. Galectin-1, a β-galactoside binding lectin, is upregulated in the endothelium of tumors of different origin and has been shown to be the target for anginex, a powerful anti-angiogenic peptide with anti-tumor activity. Here we show that when bound to anginex, galectin-1 binds various glycoproteins with hundred to thousand fold higher affinity.

Details

Authors
  • Emma Salomonsson
  • Victor L Thijssen
  • Arjan W Griffioen
  • Ulf J Nilsson
  • Hakon Leffler
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Immunology in the medical area
  • Microbiology in the medical area
Original languageEnglish
Pages (from-to)13801-13804
JournalJournal of Biological Chemistry
Volume286
Publication statusPublished - 2011
Publication categoryResearch
Peer-reviewedYes